The production of TNFα during chronic inflammation leads to organ damage due to excessive inflammation. As the first in a series of articles exploring the value of tumour necrosis factor inhibitors (anti-TNFs) in treating immune-mediated disease, this review delved into the use of these therapies for inflammatory conditions, analysing their associated safety in pregnancy.
EMJ Gastroenterology 11 [Supplement 3] . 2022
July 2022
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given